Processa Pharmaceuticals (PCSA) Enterprise Value (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Enterprise Value came in at -$1.7 million in Q1 2026, up 41.32% YoY from -$1.2 million in Q1 2025, and up 69.3% on a QoQ basis from -$5.5 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Enterprise Value (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Enterprise Value data on file, last reported at -$1.7 million in Q1 2026.
- Quarterly Enterprise Value rose 41.32% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 million (up 41.32% YoY) and the FY2025 annual result came in at -$5.5 million, down 364.77% from the prior year.
- Enterprise Value improved to -$1.7 million in Q1 2026, from -$5.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.2 million in Q4 2024 to a low of -$14.4 million in Q1 2022.
- A 5-year average of -$6.8 million and a median of -$6.5 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value surged 74.69% — and 2025, when it slumped 364.77%.
- Tracing PCSA's Enterprise Value over 5 years: stood at -$6.5 million in 2022, then climbed by 27.64% to -$4.7 million in 2023, then surged by 74.69% to -$1.2 million in 2024, then plunged by 364.77% to -$5.5 million in 2025, then soared by 69.3% to -$1.7 million in 2026.
- The last three Enterprise Value figures came in at -$1.7 million (Q1 2026), -$5.5 million (Q4 2025), and -$6.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.12 Bn |
| 10 | Processa Pharmaceuticals | 5.78 Mn | 5.78 Mn | - | -196,325.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.70 Mn |
| Dec 31, 2025 | -5.54 Mn |
| Sep 30, 2025 | -6.31 Mn |
| Jun 30, 2025 | -6.90 Mn |
| Mar 31, 2025 | -2.90 Mn |
| Dec 31, 2024 | -1.19 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | -5.57 Mn |
| Mar 31, 2024 | -8.90 Mn |
| Dec 31, 2023 | -4.71 Mn |
| Sep 30, 2023 | -6.86 Mn |
| Jun 30, 2023 | -8.70 Mn |
| Mar 31, 2023 | -10.74 Mn |
| Dec 31, 2022 | -6.50 Mn |
| Sep 30, 2022 | -9.05 Mn |
| Jun 30, 2022 | -12.06 Mn |
| Mar 31, 2022 | -14.39 Mn |
| Dec 31, 2021 | -16.50 Mn |
| Sep 30, 2021 | -19.09 Mn |
| Jun 30, 2021 | -20.83 Mn |